Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Protein Degradation and Inhibitors · Peptidase Inhibition and Analysis · Ubiquitin and proteasome pathways
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis10.1001/jama.2016.13985 ↗
2. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future10.1093/eurheartj/ehv174 ↗
3. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia10.1373/clinchem.2014.225946 ↗
4. Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro10.1016/j.chembiol.2013.11.014 ↗
5. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor10.1074/jbc.M113.514067 ↗
6. The PCSK9 decade10.1194/jlr.R026658 ↗
7. PCSK9: a key modulator of cardiovascular health10.1161/CIRCRESAHA.114.301621 ↗
8. Small molecules as inhibitors of PCSK9: Current status and future challenges10.1016/j.ejmech.2018.11.011 ↗
9. Molecular basis for LDL receptor recognition by PCSK910.1073/pnas.0712064105 ↗
10. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events10.1056/NEJMoa1501031 ↗
11. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease10.1056/NEJMoa1615664 ↗
12. H. Liu, G. Li, J. Wang, J. Liu, Berberine Derivatives Useful For Modulating Lipid Levels and Their Methods of Synthesis, 2011.
13. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?10.1021/acs.jmedchem.7b01272 ↗
14. Proteolysis targeting chimeras (PROTACs) in “beyond rule-of-five” chemical space: recent progress and future challenges10.1016/j.bmcl.2019.04.030 ↗
15. From screening to targeted degradation: strategies for the discovery and optimization of small molecule ligands for PCSK910.1016/j.chembiol.2019.10.002 ↗
16. Synthesis and cytotoxicity evaluation of novel 1, 8-acridinedione derivatives bearing phthalimide moiety as potential antitumor agents10.1038/s41598-023-41970-0 ↗
17. Acridine and acridinones: old and new structures with antimalarial activity10.2174/1874104501105010011 ↗
18. Microwave assisted solvent and catalyst free method for novel classes of β-enaminoester and acridinedione synthesis10.1039/c3ra23484c ↗
19. Frisch · 2016
20. Explicit-solvent molecular dynamics simulations revealed conformational regain and aggregation inhibition of I113T SOD1 by Himalayan bioactive molecules10.1016/j.molliq.2021.116798 ↗
21. Structure restoration and aggregate inhibition of V30M mutant transthyretin protein by potential quinoline molecules10.1016/j.ijbiomac.2023.123318 ↗
22. GROMACS: fast, flexible, and free10.1002/jcc.20291 ↗
23. GROMOS96 43a1 performance on the characterization of glycoprotein conformational ensembles through molecular dynamics simulations10.1016/j.carres.2008.12.025 ↗
24. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes10.1107/S0907444904011679 ↗
25. Molecular dynamics with coupling to an external bath10.1063/1.448118 ↗
26. A smooth particle mesh Ewald method10.1063/1.470117 ↗
27. g_mmpbsa —a GROMACS tool for high-throughput MM-PBSA calculations10.1021/ci500020m ↗
28. Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling10.1039/C7CP05418A ↗
29. Zinc ion-induced conformational changes in new Delphi metallo-β-lactamase 1 probed by molecular dynamics simulations and umbrella sampling10.1039/C6CP08105C ↗
30. Unveiling the Intricate Supramolecular Chemistry of γ-Cyclodextrin-Epigallocatechin Gallate Inclusion Complexes10.1021/acs.iecr.3c04236 ↗
31. Integrating microsecond timescale classical and biased molecular dynamics simulations to screen potential molecules for BRD4-BD110.1016/j.chaos.2022.113061 ↗
32. THE weighted histogram analysis method for free-energy calculations on biomolecules. I. The method10.1002/jcc.540130812 ↗
33. Extension to the weighted histogram analysis method: combining umbrella sampling with free energy calculations10.1016/S0010-4655(00)00215-0 ↗
34. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells10.1097/MOL.0000000000000114 ↗
35. Steered molecular dynamics simulations for uncovering the molecular mechanisms of drug dissociation and for drug screening: a test on the focal adhesion kinase10.1002/jcc.25201 ↗
36. Molecular dynamics simulations in drug discovery and pharmaceutical development10.3390/pr9010071 ↗
37. Radius of gyration as an indicator of protein structure compactness10.1134/S0026893308040195 ↗
38. Relative solvent accessible surface area predicts protein conformational changes upon binding10.1016/j.str.2011.03.010 ↗
39. Advancing targeted protein degradation for cancer therapy10.1038/s41568-021-00365-x ↗
40. PROTACs and other chemical protein degradation technologies for the treatment of neurodegenerative disorders10.1002/anie.202004746 ↗
41. Ubiquilin-mediated small molecule inhibition of mammalian target of rapamycin complex 1 (mTORC1) Signaling10.1074/jbc.M115.691584 ↗
42. Inhibitor mediated protein degradation10.1016/j.chembiol.2012.04.008 ↗
43. Boc3Arg-linked ligands induce degradation by localizing target proteins to the 20S proteasome10.1021/acschembio.6b00656 ↗
44. An overview of PROTACs: a promising drug discovery paradigm10.1186/s43556-022-00112-0 ↗
45. PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies10.3390/molecules28104014 ↗